{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,9]],"date-time":"2025-12-09T08:25:50Z","timestamp":1765268750781},"reference-count":14,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,5,31]]},"DOI":"10.7759\/cureus.15358","type":"journal-article","created":{"date-parts":[[2021,5,31]],"date-time":"2021-05-31T20:46:16Z","timestamp":1622493976000},"source":"Crossref","is-referenced-by-count":4,"title":["Immunotherapy-Induced Acute Tubulointerstitial Nephritis"],"prefix":"10.7759","author":[{"given":"Kevin","family":"Parza","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kevin","family":"Dao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pooja","family":"Patel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicolina","family":"Scibelli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrew","family":"Mangano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maryam","family":"Gondal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1606774","article-title":"Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer","volume":"375","author":"Reck M","year":"2016","unstructured":"Reck M, Rodr\u00edguez-Abreu D, Robinson AG, et al.. Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer. N Engl J Med. 2016, 375:1823-3. 10.1056\/NEJMoa1606774","journal-title":"N Engl J Med"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1412082","article-title":"Nivolumab in previously untreated melanoma without BRAF mutation","volume":"372","author":"Robert C","year":"2015","unstructured":"Robert C, Long GV, Brady B, et al.. Nivolumab in previously untreated melanoma without BRAF mutation. N Engl J Med. 2015, 372:320-30. 10.1056\/NEJMoa1412082","journal-title":"N Engl J Med"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.2019070676","article-title":"Clinical Features and Outcomes of Immune Checkpoint Inhibitor-Associated AKI: A Multicenter Study","volume":"31","author":"Cortazar FB","year":"2020","unstructured":"Cortazar FB, Kibbelaar ZA, Glezerman IG, et al.. Clinical Features and Outcomes of Immune Checkpoint Inhibitor-Associated AKI: A Multicenter Study. J Am Soc Nephrol. 2020, 31:435-46. 10.1681\/ASN.2019070676","journal-title":"J Am Soc Nephrol"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2016.72.1167","article-title":"Pooled analysis safety profile of nivolumab and ipilimumab combination therapy in patients with advanced melanoma","volume":"35","author":"Sznol M","year":"2017","unstructured":"Sznol M, Ferrucci PF, Hogg D, et al.. Pooled analysis safety profile of nivolumab and ipilimumab combination therapy in patients with advanced melanoma. J Clin Oncol. 2017, 35:3815-22. 10.1200\/JCO.2016.72.1167","journal-title":"J Clin Oncol"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2019-0027","article-title":"Amplifying outcomes: checkpoint inhibitor combinations in first-line non-small cell lung cancer","volume":"25","author":"Melosky B","year":"2020","unstructured":"Melosky B, Juergens R, Hirsh V, et al.. Amplifying outcomes: checkpoint inhibitor combinations in first-line non-small cell lung cancer. Oncologist. 2020, 25:64-77. 10.1634\/theoncologist.2019-0027","journal-title":"Oncologist"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1186\/s40425-018-0343-9","article-title":"Cytokine release syndrome","volume":"6","author":"Shimabukuro-Vornhagen A","year":"2018","unstructured":"Shimabukuro-Vornhagen A, G\u00f6del P, Subklewe M, et al.. Cytokine release syndrome. J Immunother Cancer. 2018, 6:56. 10.1186\/s40425-018-0343-9","journal-title":"J Immunother Cancer"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1703481","article-title":"Immune-related adverse events associated with immune checkpoint blockade","volume":"378","author":"Postow MA","year":"2018","unstructured":"Postow MA, Sidlow R, Hellmann MD. Immune-related adverse events associated with immune checkpoint blockade. N Engl J Med. 2018, 378:158-6. 10.1056\/NEJMra1703481","journal-title":"N Engl J Med"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2018-0764","article-title":"Diagnosis and management of immune checkpoint inhibitor-associated renal toxicity: illustrative case and review","volume":"24","author":"Sise ME","year":"2019","unstructured":"Sise ME, Seethapathy H, Reynolds KL. Diagnosis and management of immune checkpoint inhibitor-associated renal toxicity: illustrative case and review. Oncologist. 2019, 24:735-42. 10.1634\/theoncologist.2018-0764","journal-title":"Oncologist"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.2215\/CJN.00830110","article-title":"Chronic kidney disease: an inherent risk factor for acute kidney injury?","volume":"5","author":"Singh P","year":"2010","unstructured":"Singh P, Rifkin DE, Blantz RC. Chronic kidney disease: an inherent risk factor for acute kidney injury?. Clin J Am Soc Nephrol. 2010, 5:1690-5. 10.2215\/CJN.00830110","journal-title":"Clin J Am Soc Nephrol"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1186\/s12882-018-0848-y","article-title":"Immune checkpoint inhibitor (nivolumab)-associated kidney injury and the importance of recognizing concomitant medications known to cause acute tubulointerstitial nephritis: a case report","volume":"19","author":"Koda R","year":"2018","unstructured":"Koda R, Watanabe H, Tsuchida M, et al.. Immune checkpoint inhibitor (nivolumab)-associated kidney injury and the importance of recognizing concomitant medications known to cause acute tubulointerstitial nephritis: a case report. BMC Nephrol. 2018, 19:48. 10.1186\/s12882-018-0848-y","journal-title":"BMC Nephrol"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1053\/j.ajkd.2016.02.057","article-title":"Association of acute interstitial nephritis with programmed cell death 1 inhibitor therapy in lung cancer patients","volume":"68","author":"Shirali AC","year":"2016","unstructured":"Shirali AC, Perazella MA, Gettinger S. Association of acute interstitial nephritis with programmed cell death 1 inhibitor therapy in lung cancer patients. Am J Kidney Dis. 2016, 68:287-91. 10.1053\/j.ajkd.2016.02.057","journal-title":"Am J Kidney Dis"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1504030","article-title":"Combined nivolumab and ipilimumab or monotherapy in untreated melanoma","volume":"373","author":"Larkin J","year":"2015","unstructured":"Larkin J, Chiarion-Sileni V, Gonzalez R, et al.. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N Engl J Med. 2015, 373:23-34. 10.1056\/NEJMoa1504030","journal-title":"N Engl J Med"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1053\/j.ackd.2016.08.003","article-title":"Clinical approach to diagnosing acute and chronic tubulointerstitial disease","volume":"24","author":"Perazella MA","year":"2017","unstructured":"Perazella MA. Clinical approach to diagnosing acute and chronic tubulointerstitial disease. Adv Chronic Kidney Dis. 2017, 24:57-63. 10.1053\/j.ackd.2016.08.003","journal-title":"Adv Chronic Kidney Dis"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1186\/s40425-017-0300-z","article-title":"Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group","volume":"5","author":"Puzanov I","year":"2017","unstructured":"Puzanov I, Diab A, Abdallah K, et al.. Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group. J Immunother Cancer. 2017, 5:95. 10.1186\/s40425-017-0300-z","journal-title":"J Immunother Cancer"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/60226-immunotherapy-induced-acute-tubulointerstitial-nephritis","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T19:29:25Z","timestamp":1707506965000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/60226-immunotherapy-induced-acute-tubulointerstitial-nephritis"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5,31]]},"references-count":14,"URL":"https:\/\/doi.org\/10.7759\/cureus.15358","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2021,5,31]]}}}